世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

PCR技術市場：技術別（コンベンショナル、qPCR、dPCR）、製品別（装置、試薬、ソフトウェア）、アプリケーション別（遺伝子型判定、シーケンス、遺伝子発現、診断）、エンドユーザー別（アカデミア、ファーマ・バイオテック、アプライド）-2027年までの世界市場予測


PCR Technologies Market by Technique (Conventional, qPCR, dPCR), Product (Instrument, Reagents, Software), Application (Genotyping, Sequencing, Gene Expression, Diagnostics), End User (Academia, Pharma-Biotech, Applied) - Global Forecast to 2027

PCRテクノロジーの世界市場は、2022年の推定125億米ドルから2027年には183億米ドルに達し、2022年から2027年までのCAGRは8.0%と予測されています。市場成長の主な要因は、対象となる感染症や遺伝性疾患の発生率の... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年11月17日 US$4,950
シングルユーザーライセンス
ライセンス・価格情報
注文方法はこちら 		241 164 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

PCRテクノロジーの世界市場は、2022年の推定125億米ドルから2027年には183億米ドルに達し、2022年から2027年までのCAGRは8.0%と予測されています。市場成長の主な要因は、対象となる感染症や遺伝性疾患の発生率の上昇、PCR技術の継続的な進歩、投資の増加です。また、新興国での市場浸透の高まりは、PCRテクノロジー市場のプレイヤーに成長機会を提供すると期待されています。

POC検査は、特にタイムリーな医療へのアクセスが課題であり、医療インフラが古くまばらな発展途上国において、感染症の管理を大幅に改善することができます。UNAIDSによると、2018年、東・南アフリカのHIV感染者は約2,060万人でした。2019年には、中東・北アフリカで2万人の新規HIV感染者が登録されました（出典：UNAIDS Data 2020）。アジア太平洋地域では、2019年にインドと中国が主導して、推定580万人がHIVに感染していました。UNAIDSによると、2019年、インドでは約210万人がHIVに感染しています。HIVの高い感染率は、ポイントオブケア診断薬の需要を押し上げ、HIV感染症の治療をさらに加速させると思われます。

以下に、発展途上国における主要な感染症に関連する重要な統計データを掲載します。
WHOによると、インドは結核の負担が最も大きく、2020年には264万人の患者が発生すると推定されています。
- 2019年には、東南アジアで約430万人の新規結核患者が報告され、この地域で結核感染症が原因で63万2000人が死亡しています（出典：WHO）。
- 国家インフルエンザ政策2017によると、南アフリカでは毎年約1万人の死亡と4万人の入院がインフルエンザが原因で起こっています。
- WHOによると、東南アジアでは120万人がマラリアに苦しんでおり、インドだけで全マラリア患者の〜76%を占めています。
- 2014年から2016年にかけて、西アフリカでは地域最大のエボラ出血熱の流行が報告され、2年半の間に28,600人以上の患者と11,325人の死者が出ています。
- 2020年、ブラジルでは推定15,898人がジカウイルス感染症のリスクにさらされ、前年に報告された30,000人以上の症例から減少しました。

感染症の高い流行率と、発展途上国の不十分な医療インフラ設備が相まって、POC検査の普及が進むと予想されます。

"2021年のPCRテクノロジー市場の製品別シェアは、試薬・消耗品部門が最も高い"

PCRテクノロジー市場は、製品に基づき、機器、試薬・消耗品、ソフトウェア・サービスに区分されます。2021年のPCRテクノロジー市場の製品別シェアは、研究者や製薬・バイオテクノロジー企業におけるdPCRアプリケーションの増加や、dPCRベースの分析手法の需要拡大などの要因から、試薬・消耗品部門が最も大きなシェアを占めています。また、PCR装置の購入時にPCR試薬がバンドルされることや、装置のアップグレード時にPCR試薬の長期販売契約が結ばれることも、主要市場におけるPCR試薬・消耗品の採用を促す大きな要因となっている。

"2021年のPCR技術市場において、手法別ではリアルタイムPCR（qPCR）分野が最大のシェアを占めている"

PCRテクノロジー市場は、手法別に、コンベンショナルPCR、リアルタイムPCR（qPCR）、デジタルPCR（dPCR）、逆転写PCR（RT-PCR）、ホットスタートPCR、マルチプレックスPCR、その他のPCR手法に区分される。2021年の市場では、リアルタイムPCR（qPCR）分野が最も大きなシェアを占めています。ラボ技術の自動化の進展、リアルタイム解析と解析時間の短縮によるqPCRアプリケーションの拡大、qPCRベースの研究に対する資金や投資の増加、プローブベースのマルチプレックス遺伝子解析手順の増加、qPCR装置の大規模な設置ベースなどの要因が、リアルタイムPCR市場の成長を促進すると予測されている。

"2021年のPCR技術の世界市場において、用途別では診断用途分野が最大のシェアを占めている"

PCRテクノロジー市場は、アプリケーション別に、遺伝子発現解析、遺伝子配列解析、ジェノタイピング、核酸検出、核酸合成、規格検証・確認、診断アプリケーション、環境アプリケーション、その他のアプリケーションに区分される。2021年の市場では、診断用途のセグメントが最大のシェアを占めています。主な要因は、従来のDNA定量技術から、出生前スクリーニング検査、病原体の迅速検出、疾病診断、輸血時の血液由来疾患の特定など、さまざまな診断用途を持つ高度な診断技術へと大きく進化していることである。

"エンドユーザー別では、2021年に、病院と診断センターセグメントが、世界のPCRテクノロジー市場で最大のシェアを占めました"

エンドユーザーに基づいて、PCRテクノロジー市場は、病院と診断センター、ヘルスケア産業、学術・政府機関、製薬・バイオテクノロジー企業、応用産業、その他のエンドユーザーに区分されます。2021年のPCRテクノロジー市場では、病院・診断センター部門が最大のシェアを占めています。臨床診断のためのqPCR試薬市場の利用可能性の上昇、新興国における継続的な医療インフラの拡大、qPCR試薬の継続的なコスト削減は、このセグメントを推進する要因の1つである。

"アジア太平洋地域は予測期間中に最も高いCAGRで成長すると予想される"

世界のPCRテクノロジー市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに区分されます。2021年には、北米が最大のシェアを占め、欧州がそれに続きました。しかし、アジア太平洋地域は、予測期間中に最も速いCAGRで成長すると予想されます。このセグメントの高成長は、主にアジア新興国での医療インフラ拡張の進行、中国、インド、日本などの国々でのゲノムおよびがん研究プロジェクトの増加、アジア太平洋地域の新興国でのゲノムベースの研究に対する政府の継続的支援、大手医薬品製造会社によるアジアに拠点を置くCROへの臨床研究アウトソーシングの増加によるものです。

本レポートで参照した主な参加企業の内訳は以下のとおりです。
- 企業タイプ別Tier 1-48%, Tier 2-36%, Tier 3-16
- 役職別役職別：Cレベル-10%、ディレクターレベル-14%、その他-76
- 地域別北米-40％、欧州-32％、アジア太平洋-20％、中南米-5％、中東・アフリカ-3％。

2021年現在、PCRテクノロジー市場は、Thermo Fisher Scientific, Inc.（米国）、F. Hoffman-La Roche Ltd. （スイス）、Bio-Rad Laboratories, Inc.(スイス）、Bio-Rad Laboratories, Inc.（米国）、QIAGEN N.V.（ドイツ）、タカラバイオ株式会社（日本）です。その他、Agilent Technologies, Inc.（米国）、bioMérieux S.A.（フランス）、Fluidigm Corporation（米国）、Danaher Corporation（米国）、Abbott Laboratories（米国）、Merck KGaA（ドイツ）、Becton Dickinson and Company（米国）、Promega Corporation（米国）、Eppendorf AG（ドイツ）およびAnalytik Jena AG（ドイツ）等が主要プレーヤーとして挙げられます。

調査対象

本レポートでは、PCRテクノロジー市場を製品、技術、アプリケーション、エンドユーザー、地域に基づいて調査しています。また、市場成長に影響を与える要因を網羅し、市場における様々な機会や課題を分析し、市場リーダー向けの競争環境の詳細を提供します。さらに、個々の成長動向に関してマイクロマーケットを分析し、主要5地域（およびこれらの地域のそれぞれの国）に関して市場セグメントの売上を予測しています。
本レポートを購入する理由
本レポートは、既存企業だけでなく、新規参入企業や小規模企業も市場の動向を把握することができ、ひいてはより大きな市場シェアを獲得するのに役立つものと思われます。本レポートを購入された企業は、以下の戦略の1つまたは複数を組み合わせて、市場での存在感を高めることができます。

本レポートでは、以下のポイントに関する洞察を提供しています。
市場浸透度。PCR技術市場のトッププレイヤーが提供する製品ポートフォリオに関する包括的な情報
製品開発/イノベーション。PCR技術市場における今後の動向、R&D活動、製品発表に関する詳細な洞察
市場開発。有利な新興地域に関する包括的な情報
市場の多様化。PCR技術市場における新製品、成長地域、最近の開発に関する詳細な情報
競争力のある評価。市場セグメント、成長戦略、収益分析、主要な市場プレイヤーの製品に関する詳細な評価。

ページTOPに戻る


目次

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS AND EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 29
1.5 KEY STAKEHOLDERS 29
1.6 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Indicative list of secondary sources 33
2.1.2 PRIMARY DATA 34
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET ESTIMATION METHODOLOGY 35
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 36
2.2.2 USAGE-BASED MARKET ESTIMATION 37
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL PCR TECHNOLOGIES MARKET 38
2.2.3 PRIMARY RESEARCH VALIDATION 38
2.3 DATA TRIANGULATION 39
FIGURE 5 DATA TRIANGULATION METHODOLOGY 39
2.4 RESEARCH ASSUMPTIONS 40
2.5 RESEARCH LIMITATIONS 40
3 EXECUTIVE SUMMARY 41
FIGURE 6 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2021 VS. 2027 (USD MILLION) 41
FIGURE 7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2021 VS. 2027 (USD MILLION) 42
FIGURE 8 PCR TECHNOLOGIES MARKET, BY END USER, 2021 VS. 2027 (USD MILLION) 43
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF PCR TECHNOLOGIES MARKET 44
4 PREMIUM INSIGHTS 45
4.1 PCR TECHNOLOGIES MARKET OVERVIEW 45
FIGURE 10 RISING INCIDENCE OF TARGET INFECTIOUS DISEASES AND GENETIC DISORDERS TO DRIVE MARKET GROWTH 45
4.2 PCR TECHNOLOGIES MARKET SHARE, BY TECHNIQUE, 2021 VS. 2027 46
FIGURE 11 REAL-TIME PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF PCR TECHNOLOGIES MARKET IN 2021 46
4.3 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2021 VS. 2027 (USD MILLION) 47
FIGURE 12 DIAGNOSTIC APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 47
4.4 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER AND COUNTRY (2021) 48
FIGURE 13 HOSPITALS AND DIAGNOSTIC CENTERS ARE LARGEST END-USERS OF PCR TECHNOLOGIES IN ASIA PACIFIC 48
4.5 PCR TECHNOLOGIES MARKET, BY REGION 49
FIGURE 14 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD (2022–2027) 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 15 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2.1 DRIVERS 51
5.2.1.1 Rising incidence of target infectious diseases and genetic disorders 51
FIGURE 16 GLOBAL BURDEN OF HIV INFECTIONS, BY REGION, 2021 51
FIGURE 17 GROWING GERIATRIC POPULATION ACROSS KEY GEOGRAPHIES, 2019 VS. 2050 (MILLION) 52
5.2.1.2 Continuous advancements in PCR technologies 52
TABLE 1 TRADITIONAL PCR VS. QPCR AND DPCR 53
5.2.1.3 Increasing investments, funds, and grants 54
5.2.1.4 Increasing use of biomarker profiling for disease diagnostics 54
5.2.1.5 Successful completion of Human Genome Project 55
5.2.2 RESTRAINTS 55
5.2.2.1 High device costs associated with dPCR 55
5.2.2.2 Technical limitations of qPCR and dPCR 56
5.2.3 OPPORTUNITIES 56
5.2.3.1 Growing market penetration in emerging countries 56
5.2.3.2 Shift from plant-derived to genome-based drug discovery 56
5.2.4 CHALLENGES 57
5.2.4.1 Adoption and implementation of MIQE guidelines 57
5.3 TECHNOLOGY ANALYSIS 57
5.3.1 DEVELOPMENT OF PORTABLE INSTRUMENTS USING PCR DIAGNOSTIC SERVICES 57
5.3.2 DEVELOPMENT OF RAPID AND SENSITIVE DIAGNOSTIC KITS 58
5.4 GLOBAL REGULATORY LANDSCAPE 59
5.4.1 KEY REGULATORY AGENCIES 59
5.5 VALUE CHAIN ANALYSIS 60
FIGURE 18 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION AND DISTRIBUTION STAGES 60
5.6 SUPPLY CHAIN ANALYSIS 61
5.6.1 PROMINENT COMPANIES 61
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 61
5.6.3 END USERS 61
FIGURE 19 SUPPLY CHAIN ANALYSIS 61
5.7 PRICING TREND ANALYSIS 62
TABLE 2 AVERAGE PRICE OF PCR PRODUCTS, BY KEY PLAYER, 2021 (USD) 62
FIGURE 20 AVERAGE PRICE OF DIFFERENT PCR ANALYZERS, BY TECHNOLOGY, 2021 (USD) 62
5.8 REIMBURSEMENT SCENARIO 63
TABLE 3 REIMBURSEMENT CODES FOR COVID-19 PCR TESTING IN US (AS OF 2022) 63
5.9 ECOSYSTEM COVERAGE: PARENT MARKET 64
5.10 PORTER’S FIVE FORCES ANALYSIS 65
5.10.1 OVERVIEW 65
TABLE 4 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.10.2 DEGREE OF COMPETITION 65
5.10.3 BARGAINING POWER OF SUPPLIERS 65
5.10.4 BARGAINING POWER OF BUYERS 66
5.10.5 THREAT OF NEW ENTRANTS 66
5.10.6 THREAT OF SUBSTITUTES 66
5.11 PATENT ANALYSIS 66
FIGURE 21 NUMBER OF PATENTS FOR PCR TESTING 66
FIGURE 22 NUMBER OF PATENTS FOR PCR DIAGNOSTICS 67
5.12 TRADE ANALYSIS 67
TABLE 5 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD) 67
TABLE 6 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD) 68
5.13 KEY CONFERENCES AND EVENTS (2022–2023) 68
TABLE 7 PCR TECHNOLOGIES MARKET: LIST OF MAJOR CONFERENCES AND EVENTS 68
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69
5.14.1 DEVELOPMENT OF COMPACT, PORTABLE, AND LAB-ON-CHIP PCR DEVICES 69
5.14.2 ONGOING TECHNOLOGICAL INTEGRATION WITH PCR PROCESS 69
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 70
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS, BY END USER 70
FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER 70
TABLE 8 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER (%) 70
5.15.2 BUYING CRITERIA 71
FIGURE 24 KEY BUYING CRITERIA, BY END USER 71
TABLE 9 KEY BUYING CRITERIA, BY END USER 71
6 PCR TECHNOLOGIES MARKET, BY PRODUCT 72
6.1 INTRODUCTION 73
TABLE 10 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 73
6.2 REAGENTS AND CONSUMABLES 73
6.2.1 INCREASING NUMBER OF ANALYTICAL PROCEDURES AMONG RESEARCHERS TO FUEL MARKET GROWTH 73
TABLE 11 PCR REAGENTS AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 74
6.3 INSTRUMENTS 74
6.3.1 INCREASING AVAILABILITY OF INNOVATIVE PCR INSTRUMENTS TO DRIVE MARKET GROWTH 74
TABLE 12 PCR INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 75
6.4 SOFTWARE AND SERVICES 75
6.4.1 AUTOMATION AND DIGITALIZATION OF LABORATORY PROCESSES TO FUEL ADOPTION AMONG END USERS 75
TABLE 13 PCR SOFTWARE AND SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 76
7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE 77
7.1 INTRODUCTION 78
TABLE 14 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 78
7.2 CONVENTIONAL PCR 78
7.2.1 DIVERSE APPLICATIONS OF CONVENTIONAL PCR TO SUSTAIN MARKET GROWTH 78
TABLE 15 CONVENTIONAL PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 16 CONVENTIONAL PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 79
TABLE 17 CONVENTIONAL PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 80
TABLE 18 CONVENTIONAL PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 80
7.3 REAL-TIME PCR 81
7.3.1 GROWING ADOPTION AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO FUEL MARKET GROWTH 81
TABLE 19 REAL-TIME PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 20 REAL-TIME PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 82
TABLE 21 REAL-TIME PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 82
TABLE 22 REAL-TIME PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 83
7.4 DIGITAL PCR 83
7.4.1 ONGOING TECHNOLOGICAL DEVELOPMENTS WITH RESPECT TO DIGITAL PCR TO DRIVE MARKET GROWTH 83
TABLE 23 DIGITAL PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 24 DIGITAL PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 84
TABLE 25 DIGITAL PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85
TABLE 26 DIGITAL PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 85
7.5 REVERSE TRANSCRIPTION PCR 86
7.5.1 HIGHER SENSITIVITY FOR MRNA DETECTION TO DRIVE MARKET GROWTH 86
TABLE 27 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR 86
TABLE 28 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 29 REVERSE TRANSCRIPTION PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 87
TABLE 30 REVERSE TRANSCRIPTION PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88
TABLE 31 REVERSE TRANSCRIPTION PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 88
7.6 HOT-START PCR 89
7.6.1 HASSLE-FREE SETUP OF SAMPLES KEY ADVANTAGE OFFERED BY HOT-START PCR 89
TABLE 32 BENEFITS AND CONSIDERATIONS INVOLVED IN HOT-START TECHNOLOGY 89
TABLE 33 HOT-START PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 34 HOT-START PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 90
TABLE 35 HOT-START PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91
TABLE 36 HOT-START PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 91
7.7 MULTIPLEX PCR 92
7.7.1 COST-EFFECTIVENESS OF THIS TECHNIQUE TO DRIVE MARKET GROWTH 92
TABLE 37 MULTIPLEX PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 38 MULTIPLEX PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 93
TABLE 39 MULTIPLEX PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93
TABLE 40 MULTIPLEX PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 94
7.8 OTHER PCR TECHNIQUES 94
TABLE 41 OTHER PCR TECHNIQUES MARKET, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 42 OTHER PCR TECHNIQUES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 95
TABLE 43 OTHER PCR TECHNIQUES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
TABLE 44 OTHER PCR TECHNIQUES MARKET, BY END USER, 2020–2027 (USD MILLION) 96
8 PCR TECHNOLOGIES MARKET, BY APPLICATION 97
8.1 INTRODUCTION 98
TABLE 45 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98
8.2 GENE EXPRESSION ANALYSIS 99
8.2.1 GENE EXPRESSION ANALYSIS WIDELY USED IN EPIGENETICS, SIRNA QUANTIFICATION, MRNA ANALYSIS, AND CELL LINE VALIDATION 99
TABLE 46 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2020–2027 (USD MILLION) 99
8.3 GENETIC SEQUENCING 100
8.3.1 REDUCED COST OF SEQUENCING TO DRIVE MARKET GROWTH 100
TABLE 47 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION, 2020–2027 (USD MILLION) 100
8.4 GENOTYPING 101
8.4.1 SNP GENOTYPING CAN ACCELERATE PERSONALIZED MEDICINE DEVELOPMENT 101
TABLE 48 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION, 2020–2027 (USD MILLION) 101
8.5 NUCLEIC ACID DETECTION 102
8.5.1 PCR TECHNIQUES HAVE WIDE APPLICATIONS IN NUCLEIC ACID DETECTION 102
TABLE 49 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION, 2020–2027 (USD MILLION) 102
8.6 NUCLEIC ACID SYNTHESIS 103
8.6.1 DNA SYNTHESIS HAS OPENED AVENUES FOR PROGRESS IN BIOLOGY 103
TABLE 50 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION, 2020–2027 (USD MILLION) 103
8.7 STANDARD VALIDATION/VERIFICATION 103
8.7.1 PCR TECHNIQUES USED FOR REGIONAL/GLOBAL VALIDATION TO FRAME COMMERCIAL/NON-COMMERCIAL GUIDELINES 103
TABLE 51 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION, BY REGION, 2020–2027 (USD MILLION) 104
8.8 DIAGNOSTIC APPLICATIONS 104
8.8.1 DIAGNOSTIC APPLICATIONS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE 104
TABLE 52 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 105
8.9 ENVIRONMENTAL APPLICATIONS 105
8.9.1 PCR WIDELY USED TO DETECT PATHOGENS IN ENVIRONMENTAL SAMPLES 105
TABLE 53 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 106
8.10 OTHER APPLICATIONS 106
TABLE 54 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 107
9 PCR TECHNOLOGIES MARKET, BY END USER 108
9.1 INTRODUCTION 109
TABLE 55 PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 109
9.2 HOSPITALS AND DIAGNOSTIC CENTERS 109
9.2.1 HIGH PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH 109
TABLE 56 PCR TECHNOLOGIES MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 110
9.3 HEALTHCARE INDUSTRY 110
9.3.1 PCR HAS WIDE APPLICATIONS IN HEALTHCARE INDUSTRY 110
TABLE 57 PCR TECHNOLOGIES MARKET FOR HEALTHCARE INDUSTRY, BY REGION, 2020–2027 (USD MILLION) 111
9.4 ACADEMIA AND GOVERNMENT ORGANIZATIONS 111
9.4.1 AVAILABILITY OF COST-EFFECTIVE AND INNOVATIVE PCR PRODUCTS TO DRIVE ADOPTION 111
TABLE 58 PCR TECHNOLOGIES MARKET FOR ACADEMIA AND GOVERNMENT ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 112
9.5 PHARMA-BIOTECH COMPANIES 112
9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO FUEL ADOPTION OF PCR TECHNOLOGIES 112
TABLE 59 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2020–2027 (USD MILLION) 113
9.6 APPLIED INDUSTRIES 113
9.6.1 INCREASING ENVIRONMENTAL REGULATIONS TO DRIVE ADOPTION OF PCR TECHNIQUES 113
TABLE 60 PCR TECHNOLOGIES MARKET FOR APPLIED INDUSTRIES, BY REGION, 2020–2027 (USD MILLION) 114
9.7 OTHER END USERS 114
TABLE 61 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 115
10 PCR TECHNOLOGIES MARKET, BY REGION 116
10.1 INTRODUCTION 117
TABLE 62 PCR TECHNOLOGIES MARKET, BY REGION, 2020–2027 (USD MILLION) 117
10.2 NORTH AMERICA 118
FIGURE 25 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT 119
TABLE 63 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 64 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 120
TABLE 65 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 121
TABLE 66 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 67 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.2.1 US 122
10.2.1.1 Growing adoption of PCR techniques in research and academia to drive market growth 122
TABLE 68 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 123
10.2.2 CANADA 123
10.2.2.1 Government initiatives for supporting genomics research to propel growth 123
TABLE 69 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 124
10.3 EUROPE 124
TABLE 70 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 71 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 126
TABLE 72 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 126
TABLE 73 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 127
TABLE 74 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 127
10.3.1 GERMANY 128
10.3.1.1 Large-scale outsourcing of clinical diagnostic testing by hospitals to drive market growth 128
TABLE 75 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 128
10.3.2 UK 129
10.3.2.1 Growing focus on genomics research to support market growth 129
TABLE 76 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
10.3.3 FRANCE 130
10.3.3.1 Initiatives for developing genomic medicine to support market growth 130
TABLE 77 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 130
10.3.4 ITALY 131
10.3.4.1 Increasing R&D investments by pharmaceutical companies to propel market growth 131
TABLE 78 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 131
10.3.5 SPAIN 132
10.3.5.1 Increasing prevalence of chronic and infectious diseases to drive market growth 132
TABLE 79 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
10.3.6 REST OF EUROPE 132
TABLE 80 REST OF EUROPE: HIV AND TB INCIDENCE, BY COUNTRY, 2020 133
TABLE 81 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 133
10.4 ASIA PACIFIC 134
FIGURE 26 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT 135
TABLE 82 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 83 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 136
TABLE 84 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 137
TABLE 85 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 137
TABLE 86 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 138
10.4.1 JAPAN 138
10.4.1.1 Strong research and healthcare infrastructure to support market growth 138
TABLE 87 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 139
10.4.2 CHINA 139
10.4.2.1 Healthcare infrastructure modernization to support market growth 139
TABLE 88 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 140
10.4.3 INDIA 140
10.4.3.1 Presence of large target patient population to support market growth 140
TABLE 89 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 141
10.4.4 AUSTRALIA 141
10.4.4.1 High healthcare expenditure to drive demand for advanced healthcare technologies such as PCR 141
TABLE 90 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 142
10.4.5 SOUTH KOREA 142
10.4.5.1 Growing number of private hospitals and independent testing laboratories to drive market growth 142
TABLE 91 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
10.4.6 REST OF ASIA PACIFIC 143
TABLE 92 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 144
10.5 LATIN AMERICA 144
TABLE 93 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 94 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 145
TABLE 95 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 146
TABLE 96 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 146
TABLE 97 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 147
10.5.1 BRAZIL 147
10.5.1.1 Brazil to dominate LATAM market during forecast period 147
TABLE 98 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 148
10.5.2 MEXICO 148
10.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments 148
TABLE 99 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 149
10.5.3 REST OF LATIN AMERICA 149
TABLE 100 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 150
10.6 MIDDLE EAST & AFRICA 150
10.6.1 LOW PURCHASING POWER OF END USERS AND INFRASTRUCTURAL LIMITATIONS TO RESTRAIN MARKET GROWTH 150
TABLE 101 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 151
TABLE 102 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 151
TABLE 103 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 152
TABLE 104 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 153
11 COMPETITIVE LANDSCAPE 154
11.1 INTRODUCTION 154
FIGURE 27 KEY DEVELOPMENTS BY LEADING PLAYERS IN PCR TECHNOLOGIES MARKET, 2018–2022 155
11.2 REVENUE SHARE ANALYSIS 155
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PCR TECHNOLOGIES MARKET 156
11.3 MARKET SHARE ANALYSIS 156
FIGURE 29 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2021 156
11.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021) 157
11.4.1 STARS 158
11.4.2 EMERGING LEADERS 158
11.4.3 PERVASIVE PLAYERS 158
11.4.4 PARTICIPANTS 158
FIGURE 30 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 159
11.5 COMPETITIVE LEADERSHIP MAPPING: START-UP/SME EVALUATION QUADRANT (2021) 160
11.5.1 PROGRESSIVE COMPANIES 160
11.5.2 RESPONSIVE COMPANIES 160
11.5.3 DYNAMIC COMPANIES 160
11.5.4 STARTING BLOCKS 160
FIGURE 31 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS (2021) 161
11.6 COMPETITIVE SCENARIO 161
11.6.1 PRODUCT LAUNCHES & APPROVALS 162
11.6.2 DEALS 162
11.6.3 OTHER DEVELOPMENTS 163
12 COMPANY PROFILES 164
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS 164
12.1.1 THERMO FISHER SCIENTIFIC, INC. 164
TABLE 105 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 164
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 165
12.1.2 F. HOFFMANN-LA ROCHE LTD. 170
TABLE 106 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 170
FIGURE 33 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021) 171
12.1.3 BIO-RAD LABORATORIES, INC. 175
TABLE 107 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 175
FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 176
12.1.4 QIAGEN N.V. 180
TABLE 108 QIAGEN N.V.: BUSINESS OVERVIEW 180
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 181
12.1.5 TAKARA BIO, INC. 185
TABLE 109 TAKARA BIO, INC.: BUSINESS OVERVIEW 185
FIGURE 36 TAKARA BIO, INC.: COMPANY SNAPSHOT (2021) 186
12.1.6 AGILENT TECHNOLOGIES, INC. 188
TABLE 110 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 188
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 189
12.1.7 BIOMÉRIEUX S.A. 193
TABLE 111 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW 193
FIGURE 38 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2021) 194
12.1.8 FLUIDIGM CORPORATION 196
TABLE 112 FLUIDIGM CORPORATION: BUSINESS OVERVIEW 196
FIGURE 39 FLUIDIGM CORPORATION: COMPANY SNAPSHOT (2021) 197
12.1.9 DANAHER CORPORATION 200
TABLE 113 DANAHER CORPORATION: BUSINESS OVERVIEW 200
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 201
12.1.10 ABBOTT LABORATORIES 204
TABLE 114 ABBOTT LABORATORIES: BUSINESS OVERVIEW 204
FIGURE 41 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 205
12.1.11 MERCK KGAA 208
TABLE 115 MERCK KGAA: BUSINESS OVERVIEW 208
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2021) 209
12.1.12 BECTON, DICKINSON AND COMPANY 212
TABLE 116 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 212
FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 213
12.1.13 PROMEGA CORPORATION 215
TABLE 117 PROMEGA CORPORATION: BUSINESS OVERVIEW 215
12.1.14 EPPENDORF AG 218
TABLE 118 EPPENDORF AG: BUSINESS OVERVIEW 218
FIGURE 44 EPPENDORF AG: COMPANY SNAPSHOT (2021) 218
12.1.15 ANALYTIK JENA AG (A WHOLLY OWNED SUBSIDIARY OF ENDRESS+HAUSER AG) 220
TABLE 119 ENDRESS+HAUSER: BUSINESS OVERVIEW 220
FIGURE 45 ENDRESS+HAUSER: COMPANY SNAPSHOT (2021) 221
12.2 OTHER PLAYERS 223
12.2.1 MERIDIAN BIOSCIENCE, INC. 223
12.2.2 STILLA TECHNOLOGIES 224
12.2.3 JN MEDSYS 224
12.2.4 AVANCE BIOSCIENCES INC. 225
12.2.5 LGC BIOSEARCH TECHNOLOGIES 226
12.2.6 AZURA GENOMICS INC. 227
12.2.7 BIONEER CORPORATION 228
12.2.8 BLUE-RAY BIOTECH 230
12.2.9 LUMINEX CORPORATION (A DIASORIN COMPANY) 231
12.2.10 BIO MOLECULAR SYSTEMS 231
12.2.11 AZURE BIOSYSTEMS 232
12.2.12 CHAI INC. 232
12.2.13 ENZO LIFE SCIENCES 233
12.2.14 BIOMEME, INC. 234
12.2.15 ELITECH GROUP SAS 235
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX 236
13.1 DISCUSSION GUIDE 236
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 241
13.3 CUSTOMIZATION OPTIONS 243
13.4 RELATED REPORTS 243
13.5 AUTHOR DETAILS 245

　

ページTOPに戻る


　

Summary

The global PCR technologies Market market is expected to reach USD 18.3 billion by 2027 from an estimated USD 12.5 billion in 2022, at a CAGR of 8.0% from 2022 to 2027. Market growth is mainly driven by the rising incidence of target infectious diseases and genetic disorders, continuous advancements in PCR technologies and increasing investments. In addition, growing market penetration in emerging countries are expected to offer growth opportunities for players in the PCR technologies market.

POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. According to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. In 2019, 20,000 new HIV cases were registered in the Middle East and North Africa (Source: UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection.

Listed below are important statistics related to major infectious diseases in developing countries:
According to the WHO, India has the highest tuberculosis burden, with an estimated incidence of 2.64 million cases in 2020.
• In 2019, around 4.3 million new tuberculosis cases were reported in Southeast Asia, and 632,000 people died due to TB infections in this region (Source: WHO).
• According to the National Influenza Policy 2017, around 10,000 deaths and 40,000 hospitalizations are caused due to influenza in South Africa each year.
• According to the WHO, 1.2 million people in Southeast Asia suffer from malaria, with India alone accounting for ~76% of the total malaria cases.
• During 2014–2016, West Africa reported the largest Ebola epidemic in the region; in two and a half years, the outbreak resulted in more than 28,600 cases and 11,325 deaths.
• In 2020, an estimated 15,898 people in Brazil were at risk of Zika virus infections, down from over 30,000 cases reported a year earlier.

The high prevalence of infectious diseases, coupled with the inadequate healthcare infrastructural facilities in developing countries, is expected to drive the adoption of POC testing.

“The Reagents and Consumables segment accounted for the largest share of the PCR technologies market, by product, in 2021”

Based on products, the PCR technologies market is segmented into instruments, reagents and consumables, and software and services. In 2021, the largest share of the PCR technologies market was accounted by reagents and consumables segment, due to factors such as the increased dPCR application base and developing demand for dPCR based analytical procedures, among researchers and pharmaceutical-biotechtechnology companies. Moreover, bundle sales of PCR reagents with the purchase of PCR instruments and long term sales contract for PCR reagents upon device upgradation is also a major factor driving the adoption of PCR reagents and consumables in major markets.

“The real-time PCR (qPCR) segment accounted for the largest share of the PCR technologies market, by technique, in 2021”

Based on technique, the PCR technologies market is segmented into conventional PCR, real-time PCR (qPCR), digital PCR (dPCR), reverse transcription PCR (RT-PCR), hot-start PCR, multiplex PCR, and other PCR techniques. The real-time PCR (qPCR) segment accounted for the largest share of the market in 2021. Factors such as the ongoing automation of the laboratory techniques; expansion of qPCR applications, owing to real-time analysis and reduced analysis time; increased funding and investments for qPCR based research, rising number of probe-based multiplex genetic analysis procedures and large installation base of qPCR instruments are expected to fuel the growth of the real-time PCR market.

“The Diagnostic application segment, by application, accounted for the largest share of the global PCR technologies market in 2021”

On the basis of application, the PCR technologies market is segmented into gene expression analysis, genetic sequencing, genotyping, nucleic acid detection, nucleic acid synthesis, standard validation/verification, diagnostic applications, environmental applications, and other applications. The diagnostic application segment accounted for the largest share of the market in 2021. Major factor responsible is the significant evolution from a traditional DNA quantification technique into an advanced diagnostic technique having various diagnostic applications, such as prenatal screening test, rapid pathogen detection, disease diagnoses and the identification of blood-borne diseases during blood transfusion.

“On the basis of End Users, Hospitals and Diagnostic Centers segment accounted for the largest share of the global PCR technologies market, in 2021”

On the basis of end users, the PCR technologies market is segmented into hospitals and diagnostic centers, healthcare industry, academia and government organizations, pharma-biotech companies, applied industries, and other end users. The hospitals and diagnostic centers segment accounted for the largest share of the PCR technologies market in 2021. The rise in qPCR reagents market availability for clinical diagnostics, ongoing healthcare infrastructure expansion in emerging countries, and the continuous cost reduction of qPCR reagents are some of the factors that are driving the segment.

“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”

The global PCR technologies market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. However, the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The high growth of this segment is mainly due to the ongoing of healthcare infrastructure expansion in emerging Asian countries, increasing number of genomics and cancer research projects in countries like China, India, and Japan, continuous government support for genomics-based researches in emerging Asia Pacific countries and rising outsourcing of clinical research by leading drug manufacturing companies to Asia-based CROs.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: C-level–10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

As of 2021, the PCR technologies market is dominated by Thermo Fisher Scientific, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Germany), Takara Bio, Inc. (Japan). Other leading players are Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluidigm Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Becton Dickinson and Company (US), Promega Corporation (US), Eppendorf AG (Germany), and Analytik Jena AG (Germany).

Research Coverage

This report studies the PCR technologies market based on product, technique, application, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the PCR technologies market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the PCR technologies market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the PCR technologies market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS AND EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 YEARS CONSIDERED 28
1.4 CURRENCY CONSIDERED 29
1.5 KEY STAKEHOLDERS 29
1.6 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 1 RESEARCH DESIGN 31
2.1.1 SECONDARY DATA 32
2.1.1.1 Indicative list of secondary sources 33
2.1.2 PRIMARY DATA 34
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET ESTIMATION METHODOLOGY 35
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 36
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 36
2.2.2 USAGE-BASED MARKET ESTIMATION 37
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: GLOBAL PCR TECHNOLOGIES MARKET 38
2.2.3 PRIMARY RESEARCH VALIDATION 38
2.3 DATA TRIANGULATION 39
FIGURE 5 DATA TRIANGULATION METHODOLOGY 39
2.4 RESEARCH ASSUMPTIONS 40
2.5 RESEARCH LIMITATIONS 40
3 EXECUTIVE SUMMARY 41
FIGURE 6 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2021 VS. 2027 (USD MILLION) 41
FIGURE 7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2021 VS. 2027 (USD MILLION) 42
FIGURE 8 PCR TECHNOLOGIES MARKET, BY END USER, 2021 VS. 2027 (USD MILLION) 43
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF PCR TECHNOLOGIES MARKET 44
4 PREMIUM INSIGHTS 45
4.1 PCR TECHNOLOGIES MARKET OVERVIEW 45
FIGURE 10 RISING INCIDENCE OF TARGET INFECTIOUS DISEASES AND GENETIC DISORDERS TO DRIVE MARKET GROWTH 45
4.2 PCR TECHNOLOGIES MARKET SHARE, BY TECHNIQUE, 2021 VS. 2027 46
FIGURE 11 REAL-TIME PCR SEGMENT ACCOUNTED FOR LARGEST SHARE OF PCR TECHNOLOGIES MARKET IN 2021 46
4.3 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2021 VS. 2027 (USD MILLION) 47
FIGURE 12 DIAGNOSTIC APPLICATIONS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 47
4.4 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER AND COUNTRY (2021) 48
FIGURE 13 HOSPITALS AND DIAGNOSTIC CENTERS ARE LARGEST END-USERS OF PCR TECHNOLOGIES IN ASIA PACIFIC 48
4.5 PCR TECHNOLOGIES MARKET, BY REGION 49
FIGURE 14 ASIA PACIFIC MARKET TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD (2022–2027) 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
FIGURE 15 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
5.2.1 DRIVERS 51
5.2.1.1 Rising incidence of target infectious diseases and genetic disorders 51
FIGURE 16 GLOBAL BURDEN OF HIV INFECTIONS, BY REGION, 2021 51
FIGURE 17 GROWING GERIATRIC POPULATION ACROSS KEY GEOGRAPHIES, 2019 VS. 2050 (MILLION) 52
5.2.1.2 Continuous advancements in PCR technologies 52
TABLE 1 TRADITIONAL PCR VS. QPCR AND DPCR 53
5.2.1.3 Increasing investments, funds, and grants 54
5.2.1.4 Increasing use of biomarker profiling for disease diagnostics 54
5.2.1.5 Successful completion of Human Genome Project 55
5.2.2 RESTRAINTS 55
5.2.2.1 High device costs associated with dPCR 55
5.2.2.2 Technical limitations of qPCR and dPCR 56
5.2.3 OPPORTUNITIES 56
5.2.3.1 Growing market penetration in emerging countries 56
5.2.3.2 Shift from plant-derived to genome-based drug discovery 56
5.2.4 CHALLENGES 57
5.2.4.1 Adoption and implementation of MIQE guidelines 57
5.3 TECHNOLOGY ANALYSIS 57
5.3.1 DEVELOPMENT OF PORTABLE INSTRUMENTS USING PCR DIAGNOSTIC SERVICES 57
5.3.2 DEVELOPMENT OF RAPID AND SENSITIVE DIAGNOSTIC KITS 58
5.4 GLOBAL REGULATORY LANDSCAPE 59
5.4.1 KEY REGULATORY AGENCIES 59
5.5 VALUE CHAIN ANALYSIS 60
FIGURE 18 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING REGULATION AND DISTRIBUTION STAGES 60
5.6 SUPPLY CHAIN ANALYSIS 61
5.6.1 PROMINENT COMPANIES 61
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 61
5.6.3 END USERS 61
FIGURE 19 SUPPLY CHAIN ANALYSIS 61
5.7 PRICING TREND ANALYSIS 62
TABLE 2 AVERAGE PRICE OF PCR PRODUCTS, BY KEY PLAYER, 2021 (USD) 62
FIGURE 20 AVERAGE PRICE OF DIFFERENT PCR ANALYZERS, BY TECHNOLOGY, 2021 (USD) 62
5.8 REIMBURSEMENT SCENARIO 63
TABLE 3 REIMBURSEMENT CODES FOR COVID-19 PCR TESTING IN US (AS OF 2022) 63
5.9 ECOSYSTEM COVERAGE: PARENT MARKET 64
5.10 PORTER’S FIVE FORCES ANALYSIS 65
5.10.1 OVERVIEW 65
TABLE 4 PCR TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.10.2 DEGREE OF COMPETITION 65
5.10.3 BARGAINING POWER OF SUPPLIERS 65
5.10.4 BARGAINING POWER OF BUYERS 66
5.10.5 THREAT OF NEW ENTRANTS 66
5.10.6 THREAT OF SUBSTITUTES 66
5.11 PATENT ANALYSIS 66
FIGURE 21 NUMBER OF PATENTS FOR PCR TESTING 66
FIGURE 22 NUMBER OF PATENTS FOR PCR DIAGNOSTICS 67
5.12 TRADE ANALYSIS 67
TABLE 5 IMPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD) 67
TABLE 6 EXPORT DATA FOR PCR ANALYZERS (HS CODE 3822), BY COUNTRY, 2017–2021 (USD) 68
5.13 KEY CONFERENCES AND EVENTS (2022–2023) 68
TABLE 7 PCR TECHNOLOGIES MARKET: LIST OF MAJOR CONFERENCES AND EVENTS 68
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 69
5.14.1 DEVELOPMENT OF COMPACT, PORTABLE, AND LAB-ON-CHIP PCR DEVICES 69
5.14.2 ONGOING TECHNOLOGICAL INTEGRATION WITH PCR PROCESS 69
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 70
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS, BY END USER 70
FIGURE 23 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER 70
TABLE 8 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER (%) 70
5.15.2 BUYING CRITERIA 71
FIGURE 24 KEY BUYING CRITERIA, BY END USER 71
TABLE 9 KEY BUYING CRITERIA, BY END USER 71
6 PCR TECHNOLOGIES MARKET, BY PRODUCT 72
6.1 INTRODUCTION 73
TABLE 10 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 73
6.2 REAGENTS AND CONSUMABLES 73
6.2.1 INCREASING NUMBER OF ANALYTICAL PROCEDURES AMONG RESEARCHERS TO FUEL MARKET GROWTH 73
TABLE 11 PCR REAGENTS AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION) 74
6.3 INSTRUMENTS 74
6.3.1 INCREASING AVAILABILITY OF INNOVATIVE PCR INSTRUMENTS TO DRIVE MARKET GROWTH 74
TABLE 12 PCR INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION) 75
6.4 SOFTWARE AND SERVICES 75
6.4.1 AUTOMATION AND DIGITALIZATION OF LABORATORY PROCESSES TO FUEL ADOPTION AMONG END USERS 75
TABLE 13 PCR SOFTWARE AND SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 76
7 PCR TECHNOLOGIES MARKET, BY TECHNIQUE 77
7.1 INTRODUCTION 78
TABLE 14 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 78
7.2 CONVENTIONAL PCR 78
7.2.1 DIVERSE APPLICATIONS OF CONVENTIONAL PCR TO SUSTAIN MARKET GROWTH 78
TABLE 15 CONVENTIONAL PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 16 CONVENTIONAL PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 79
TABLE 17 CONVENTIONAL PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 80
TABLE 18 CONVENTIONAL PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 80
7.3 REAL-TIME PCR 81
7.3.1 GROWING ADOPTION AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO FUEL MARKET GROWTH 81
TABLE 19 REAL-TIME PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 81
TABLE 20 REAL-TIME PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 82
TABLE 21 REAL-TIME PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 82
TABLE 22 REAL-TIME PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 83
7.4 DIGITAL PCR 83
7.4.1 ONGOING TECHNOLOGICAL DEVELOPMENTS WITH RESPECT TO DIGITAL PCR TO DRIVE MARKET GROWTH 83
TABLE 23 DIGITAL PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 24 DIGITAL PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 84
TABLE 25 DIGITAL PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85
TABLE 26 DIGITAL PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 85
7.5 REVERSE TRANSCRIPTION PCR 86
7.5.1 HIGHER SENSITIVITY FOR MRNA DETECTION TO DRIVE MARKET GROWTH 86
TABLE 27 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR 86
TABLE 28 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 87
TABLE 29 REVERSE TRANSCRIPTION PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 87
TABLE 30 REVERSE TRANSCRIPTION PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88
TABLE 31 REVERSE TRANSCRIPTION PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 88
7.6 HOT-START PCR 89
7.6.1 HASSLE-FREE SETUP OF SAMPLES KEY ADVANTAGE OFFERED BY HOT-START PCR 89
TABLE 32 BENEFITS AND CONSIDERATIONS INVOLVED IN HOT-START TECHNOLOGY 89
TABLE 33 HOT-START PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 34 HOT-START PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 90
TABLE 35 HOT-START PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91
TABLE 36 HOT-START PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 91
7.7 MULTIPLEX PCR 92
7.7.1 COST-EFFECTIVENESS OF THIS TECHNIQUE TO DRIVE MARKET GROWTH 92
TABLE 37 MULTIPLEX PCR MARKET, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 38 MULTIPLEX PCR MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 93
TABLE 39 MULTIPLEX PCR MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93
TABLE 40 MULTIPLEX PCR MARKET, BY END USER, 2020–2027 (USD MILLION) 94
7.8 OTHER PCR TECHNIQUES 94
TABLE 41 OTHER PCR TECHNIQUES MARKET, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 42 OTHER PCR TECHNIQUES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 95
TABLE 43 OTHER PCR TECHNIQUES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96
TABLE 44 OTHER PCR TECHNIQUES MARKET, BY END USER, 2020–2027 (USD MILLION) 96
8 PCR TECHNOLOGIES MARKET, BY APPLICATION 97
8.1 INTRODUCTION 98
TABLE 45 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98
8.2 GENE EXPRESSION ANALYSIS 99
8.2.1 GENE EXPRESSION ANALYSIS WIDELY USED IN EPIGENETICS, SIRNA QUANTIFICATION, MRNA ANALYSIS, AND CELL LINE VALIDATION 99
TABLE 46 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2020–2027 (USD MILLION) 99
8.3 GENETIC SEQUENCING 100
8.3.1 REDUCED COST OF SEQUENCING TO DRIVE MARKET GROWTH 100
TABLE 47 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION, 2020–2027 (USD MILLION) 100
8.4 GENOTYPING 101
8.4.1 SNP GENOTYPING CAN ACCELERATE PERSONALIZED MEDICINE DEVELOPMENT 101
TABLE 48 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION, 2020–2027 (USD MILLION) 101
8.5 NUCLEIC ACID DETECTION 102
8.5.1 PCR TECHNIQUES HAVE WIDE APPLICATIONS IN NUCLEIC ACID DETECTION 102
TABLE 49 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION, 2020–2027 (USD MILLION) 102
8.6 NUCLEIC ACID SYNTHESIS 103
8.6.1 DNA SYNTHESIS HAS OPENED AVENUES FOR PROGRESS IN BIOLOGY 103
TABLE 50 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION, 2020–2027 (USD MILLION) 103
8.7 STANDARD VALIDATION/VERIFICATION 103
8.7.1 PCR TECHNIQUES USED FOR REGIONAL/GLOBAL VALIDATION TO FRAME COMMERCIAL/NON-COMMERCIAL GUIDELINES 103
TABLE 51 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION, BY REGION, 2020–2027 (USD MILLION) 104
8.8 DIAGNOSTIC APPLICATIONS 104
8.8.1 DIAGNOSTIC APPLICATIONS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE 104
TABLE 52 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 105
8.9 ENVIRONMENTAL APPLICATIONS 105
8.9.1 PCR WIDELY USED TO DETECT PATHOGENS IN ENVIRONMENTAL SAMPLES 105
TABLE 53 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 106
8.10 OTHER APPLICATIONS 106
TABLE 54 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 107
9 PCR TECHNOLOGIES MARKET, BY END USER 108
9.1 INTRODUCTION 109
TABLE 55 PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 109
9.2 HOSPITALS AND DIAGNOSTIC CENTERS 109
9.2.1 HIGH PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH 109
TABLE 56 PCR TECHNOLOGIES MARKET FOR HOSPITALS AND DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 110
9.3 HEALTHCARE INDUSTRY 110
9.3.1 PCR HAS WIDE APPLICATIONS IN HEALTHCARE INDUSTRY 110
TABLE 57 PCR TECHNOLOGIES MARKET FOR HEALTHCARE INDUSTRY, BY REGION, 2020–2027 (USD MILLION) 111
9.4 ACADEMIA AND GOVERNMENT ORGANIZATIONS 111
9.4.1 AVAILABILITY OF COST-EFFECTIVE AND INNOVATIVE PCR PRODUCTS TO DRIVE ADOPTION 111
TABLE 58 PCR TECHNOLOGIES MARKET FOR ACADEMIA AND GOVERNMENT ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION) 112
9.5 PHARMA-BIOTECH COMPANIES 112
9.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO FUEL ADOPTION OF PCR TECHNOLOGIES 112
TABLE 59 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2020–2027 (USD MILLION) 113
9.6 APPLIED INDUSTRIES 113
9.6.1 INCREASING ENVIRONMENTAL REGULATIONS TO DRIVE ADOPTION OF PCR TECHNIQUES 113
TABLE 60 PCR TECHNOLOGIES MARKET FOR APPLIED INDUSTRIES, BY REGION, 2020–2027 (USD MILLION) 114
9.7 OTHER END USERS 114
TABLE 61 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 115
10 PCR TECHNOLOGIES MARKET, BY REGION 116
10.1 INTRODUCTION 117
TABLE 62 PCR TECHNOLOGIES MARKET, BY REGION, 2020–2027 (USD MILLION) 117
10.2 NORTH AMERICA 118
FIGURE 25 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT 119
TABLE 63 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 64 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 120
TABLE 65 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 121
TABLE 66 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 67 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.2.1 US 122
10.2.1.1 Growing adoption of PCR techniques in research and academia to drive market growth 122
TABLE 68 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 123
10.2.2 CANADA 123
10.2.2.1 Government initiatives for supporting genomics research to propel growth 123
TABLE 69 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 124
10.3 EUROPE 124
TABLE 70 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 71 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 126
TABLE 72 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 126
TABLE 73 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 127
TABLE 74 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 127
10.3.1 GERMANY 128
10.3.1.1 Large-scale outsourcing of clinical diagnostic testing by hospitals to drive market growth 128
TABLE 75 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 128
10.3.2 UK 129
10.3.2.1 Growing focus on genomics research to support market growth 129
TABLE 76 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
10.3.3 FRANCE 130
10.3.3.1 Initiatives for developing genomic medicine to support market growth 130
TABLE 77 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 130
10.3.4 ITALY 131
10.3.4.1 Increasing R&D investments by pharmaceutical companies to propel market growth 131
TABLE 78 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 131
10.3.5 SPAIN 132
10.3.5.1 Increasing prevalence of chronic and infectious diseases to drive market growth 132
TABLE 79 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
10.3.6 REST OF EUROPE 132
TABLE 80 REST OF EUROPE: HIV AND TB INCIDENCE, BY COUNTRY, 2020 133
TABLE 81 REST OF EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 133
10.4 ASIA PACIFIC 134
FIGURE 26 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT 135
TABLE 82 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 136
TABLE 83 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 136
TABLE 84 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 137
TABLE 85 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 137
TABLE 86 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 138
10.4.1 JAPAN 138
10.4.1.1 Strong research and healthcare infrastructure to support market growth 138
TABLE 87 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 139
10.4.2 CHINA 139
10.4.2.1 Healthcare infrastructure modernization to support market growth 139
TABLE 88 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 140
10.4.3 INDIA 140
10.4.3.1 Presence of large target patient population to support market growth 140
TABLE 89 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 141
10.4.4 AUSTRALIA 141
10.4.4.1 High healthcare expenditure to drive demand for advanced healthcare technologies such as PCR 141
TABLE 90 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 142
10.4.5 SOUTH KOREA 142
10.4.5.1 Growing number of private hospitals and independent testing laboratories to drive market growth 142
TABLE 91 SOUTH KOREA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
10.4.6 REST OF ASIA PACIFIC 143
TABLE 92 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 144
10.5 LATIN AMERICA 144
TABLE 93 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 94 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 145
TABLE 95 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 146
TABLE 96 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 146
TABLE 97 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 147
10.5.1 BRAZIL 147
10.5.1.1 Brazil to dominate LATAM market during forecast period 147
TABLE 98 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 148
10.5.2 MEXICO 148
10.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments 148
TABLE 99 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 149
10.5.3 REST OF LATIN AMERICA 149
TABLE 100 REST OF LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 150
10.6 MIDDLE EAST & AFRICA 150
10.6.1 LOW PURCHASING POWER OF END USERS AND INFRASTRUCTURAL LIMITATIONS TO RESTRAIN MARKET GROWTH 150
TABLE 101 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 151
TABLE 102 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 151
TABLE 103 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 152
TABLE 104 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER, 2020–2027 (USD MILLION) 153
11 COMPETITIVE LANDSCAPE 154
11.1 INTRODUCTION 154
FIGURE 27 KEY DEVELOPMENTS BY LEADING PLAYERS IN PCR TECHNOLOGIES MARKET, 2018–2022 155
11.2 REVENUE SHARE ANALYSIS 155
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN PCR TECHNOLOGIES MARKET 156
11.3 MARKET SHARE ANALYSIS 156
FIGURE 29 PCR TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2021 156
11.4 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021) 157
11.4.1 STARS 158
11.4.2 EMERGING LEADERS 158
11.4.3 PERVASIVE PLAYERS 158
11.4.4 PARTICIPANTS 158
FIGURE 30 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 159
11.5 COMPETITIVE LEADERSHIP MAPPING: START-UP/SME EVALUATION QUADRANT (2021) 160
11.5.1 PROGRESSIVE COMPANIES 160
11.5.2 RESPONSIVE COMPANIES 160
11.5.3 DYNAMIC COMPANIES 160
11.5.4 STARTING BLOCKS 160
FIGURE 31 PCR TECHNOLOGIES MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS (2021) 161
11.6 COMPETITIVE SCENARIO 161
11.6.1 PRODUCT LAUNCHES & APPROVALS 162
11.6.2 DEALS 162
11.6.3 OTHER DEVELOPMENTS 163
12 COMPANY PROFILES 164
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS 164
12.1.1 THERMO FISHER SCIENTIFIC, INC. 164
TABLE 105 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 164
FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 165
12.1.2 F. HOFFMANN-LA ROCHE LTD. 170
TABLE 106 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 170
FIGURE 33 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2021) 171
12.1.3 BIO-RAD LABORATORIES, INC. 175
TABLE 107 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 175
FIGURE 34 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 176
12.1.4 QIAGEN N.V. 180
TABLE 108 QIAGEN N.V.: BUSINESS OVERVIEW 180
FIGURE 35 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 181
12.1.5 TAKARA BIO, INC. 185
TABLE 109 TAKARA BIO, INC.: BUSINESS OVERVIEW 185
FIGURE 36 TAKARA BIO, INC.: COMPANY SNAPSHOT (2021) 186
12.1.6 AGILENT TECHNOLOGIES, INC. 188
TABLE 110 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 188
FIGURE 37 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021) 189
12.1.7 BIOMÉRIEUX S.A. 193
TABLE 111 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW 193
FIGURE 38 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2021) 194
12.1.8 FLUIDIGM CORPORATION 196
TABLE 112 FLUIDIGM CORPORATION: BUSINESS OVERVIEW 196
FIGURE 39 FLUIDIGM CORPORATION: COMPANY SNAPSHOT (2021) 197
12.1.9 DANAHER CORPORATION 200
TABLE 113 DANAHER CORPORATION: BUSINESS OVERVIEW 200
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021) 201
12.1.10 ABBOTT LABORATORIES 204
TABLE 114 ABBOTT LABORATORIES: BUSINESS OVERVIEW 204
FIGURE 41 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 205
12.1.11 MERCK KGAA 208
TABLE 115 MERCK KGAA: BUSINESS OVERVIEW 208
FIGURE 42 MERCK KGAA: COMPANY SNAPSHOT (2021) 209
12.1.12 BECTON, DICKINSON AND COMPANY 212
TABLE 116 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 212
FIGURE 43 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 213
12.1.13 PROMEGA CORPORATION 215
TABLE 117 PROMEGA CORPORATION: BUSINESS OVERVIEW 215
12.1.14 EPPENDORF AG 218
TABLE 118 EPPENDORF AG: BUSINESS OVERVIEW 218
FIGURE 44 EPPENDORF AG: COMPANY SNAPSHOT (2021) 218
12.1.15 ANALYTIK JENA AG (A WHOLLY OWNED SUBSIDIARY OF ENDRESS+HAUSER AG) 220
TABLE 119 ENDRESS+HAUSER: BUSINESS OVERVIEW 220
FIGURE 45 ENDRESS+HAUSER: COMPANY SNAPSHOT (2021) 221
12.2 OTHER PLAYERS 223
12.2.1 MERIDIAN BIOSCIENCE, INC. 223
12.2.2 STILLA TECHNOLOGIES 224
12.2.3 JN MEDSYS 224
12.2.4 AVANCE BIOSCIENCES INC. 225
12.2.5 LGC BIOSEARCH TECHNOLOGIES 226
12.2.6 AZURA GENOMICS INC. 227
12.2.7 BIONEER CORPORATION 228
12.2.8 BLUE-RAY BIOTECH 230
12.2.9 LUMINEX CORPORATION (A DIASORIN COMPANY) 231
12.2.10 BIO MOLECULAR SYSTEMS 231
12.2.11 AZURE BIOSYSTEMS 232
12.2.12 CHAI INC. 232
12.2.13 ENZO LIFE SCIENCES 233
12.2.14 BIOMEME, INC. 234
12.2.15 ELITECH GROUP SAS 235
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX 236
13.1 DISCUSSION GUIDE 236
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 241
13.3 CUSTOMIZATION OPTIONS 243
13.4 RELATED REPORTS 243
13.5 AUTHOR DETAILS 245

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（診断薬）の最新刊レポート

MarketsandMarkets社の診断薬分野での最新刊レポート

本レポートと同じKEY WORD（pcr）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/19　10:26

155.94 円

162.31 円

199.02 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.